Last €470.00 EUR
Change Today 0.00 / 0.00%
Volume 0.0
RHPP On Other Exchanges
EN Paris
EN Paris
New York
As of 11:50 AM 06/16/14 All times are local (Market data is delayed by at least 15 minutes).

sanofi-titr part10%87 (RHPP) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/14/14 - €482.00
52 Week Low
03/11/14 - €419.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SANOFI-TITR PART10%87 (RHPP)

sanofi-titr part10%87 (RHPP) Details

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances and collaborations with Bristol-Myers Squibb, Regeneron, Warner Chilcott, Regulus Therapeutics Inc., Medtronic, Inc., UCB S.A., and Illumina, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.

112,128 Employees
Last Reported Date: 03/7/14
Founded in 1973

sanofi-titr part10%87 (RHPP) Top Compensated Officers

Chairman, Interim Chief Executive Officer, Ch...
Total Annual Compensation: €700.0K
Compensation as of Fiscal Year 2013.

sanofi-titr part10%87 (RHPP) Key Developments

Sanofi Confirms Phase III Development of Lixilan Remains on Track

Zealand Pharma A/S informed that Sanofi has confirmed that the Phase III development of LixiLan remains on track with expected completion by third quarter of 2015. LixiLan is an investigational fixed-ratio combination of insulin glargine (Lantus(r)), the basal insulin, with lixisenatide (Lyxumia(r)), a GLP-1 receptor agonist invented by Zealand, in a single daily injection for the treatment of adults with type 2 diabetes. Sanofi also stated that results from the ELIXA CV Outcome study of lixisenatide are expected in second quarter 2015 and that the company plans for an FDA submission of LixiLan as early as at the end of 2015. LixiLan was presented by Sanofi as a late-stage pipeline asset to be considered amongst the company's next wave of innovative investigational new medicines. The LixiLan Phase III program includes two studies: LixiLan-O (1,125 patients) evaluating LixiLan as a potential first injectable medicine for patients with Type 2 diabetes insufficiently controlled on oral anti-diabetes drugs (OADs), and LixiLan-L (700 patients) evaluating LixiLan as potential basal intensification for patients with Type 2 diabetes uncontrolled with basal therapy. Sanofi also provided a summary of results from the Phase IIb proof-of-concept study in 323 patients with Type 2 diabetes, presented on at ADA and at EASD earlier in 2014. Results from the study show that LixiLan gave a robust reduction in HbA1c (three months blood sugar level) from 8.1% to 6.3% with 84% of the patients on LixiLan having achieved the HbA1c target of <7%. Patients treated with LixiLan also had a reduction in body weight (-1kg) and experienced less frequent nausea and vomiting compared to what has been reported for the GLP-1 class and a low incidence rate of symptomatic hypoglycemia.

Sanofi and SERGAS Sign R&D Collaboration Agreement

Sanofi has signed a co-operation healthcare agreement with the Galician Healthcare Service (SERGAS) in Spain. The agreement will be valid until 2015 and is aimed at supporting research and development, diagnostic, and treatment of chronic conditions, with a special emphasis on diabetes.

Sanofi to Launch 18 Drugs by 2020

Sanofi announced that it expects to accrue more than EUR 30 million in sales from 18 new product roll-outs between 2014 and 2020. In particular, Sanofi's research and development pipeline will pave the way for launches of drugs and vaccines in different therapeutic areas, including rare diseases, multiple sclerosis, cardiovascular and metabolic, vaccines, immunology, and inflammation. Sanofi foresees six new launches in 2015 and an additional six new roll-outs every six months between 2016 and 2018.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHPP:FP €470.00 EUR 0.00

RHPP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $68.70 USD +0.64
Amgen Inc $164.72 USD +2.48
Bayer AG €120.06 EUR +2.24
Bristol-Myers Squibb Co $58.86 USD +0.34
Gilead Sciences Inc $100.30 USD -0.81
View Industry Companies

Industry Analysis


Industry Average

Valuation RHPP Industry Range
Price/Earnings 24.5x
Price/Sales 3.0x
Price/Book 1.9x
Price/Cash Flow 15.1x
TEV/Sales 2.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-TITR PART10%87, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at